• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tevogen Bio Holdings Inc. - Common Stock (NQ:TVGN)

    0.3217 +0.0017 (+0.53%)
    Streaming Delayed Price Updated: 9:49 AM EST, Jan 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 66,236
    Open 0.3200
    Bid (Size) 0.3185 (800)
    Ask (Size) 0.3237 (1,000)
    Prev. Close 0.3200
    Today's Range 0.3150 - 0.3232
    52wk Range 0.2990 - 1.920
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel
    In a stunning blow to the burgeoning field of allogeneic cell therapy, Atara Biotherapeutics (Nasdaq: ATRA) saw its market valuation evaporate this week following a second Complete Response Letter... 
    Via MarketMinute
    Topics Bankruptcy
    News headline image
    Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
    From Tevogen Bio Inc
    Via GlobeNewswire

    Performance

    YTD
    -11.6%
    -11.6%
    1 Month
    -19.2%
    -19.2%
    3 Month
    -57.4%
    -57.4%
    6 Month
    -73.8%
    -73.8%
    1 Year
    -74.1%
    -74.1%

    More News

    Read More
    News headline image
    Tevogen CEO Donates Shares to Support Education for Underprivileged Children
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen CEO Donates Personal Shares to Support Local Fire Department
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
    From Tevogen Bio Inc
    Via GlobeNewswire

    Frequently Asked Questions

    Is Tevogen Bio Holdings Inc. - Common Stock publicly traded?
    Yes, Tevogen Bio Holdings Inc. - Common Stock is publicly traded.
    What exchange does Tevogen Bio Holdings Inc. - Common Stock trade on?
    Tevogen Bio Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Tevogen Bio Holdings Inc. - Common Stock?
    The ticker symbol for Tevogen Bio Holdings Inc. - Common Stock is TVGN on the Nasdaq Stock Market
    What is the current price of Tevogen Bio Holdings Inc. - Common Stock?
    The current price of Tevogen Bio Holdings Inc. - Common Stock is 0.3217
    When was Tevogen Bio Holdings Inc. - Common Stock last traded?
    The last trade of Tevogen Bio Holdings Inc. - Common Stock was at 01/15/26 09:49 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.